Reglagene is revolutionizing brain disease therapy by targeting tubulin with a groundbreaking class of selective inhibitors. Our novel compounds, led by RGN6024, offer a blend of oral administration, high tolerance, and unparalleled penetration of the blood-brain barrier. Currently in preclinical development, RGN6024 shows promising potential for treating brain cancers, notably outperforming temozolomide—the current standard—in therapy-resistant glioblastoma and by halting tumor growth in a rigorous intracranial model. Supported by robust pharmacokinetic profiles in both rodent and canine studies, and a favorable maximum tolerated dose, Reglagene is advancing RGN6024 towards clinical trials, with an IND filing projected for early 2025. We are strategically capitalizing on our patented technology, with follow on products, to address critical needs in conditions characterized by neuroinflammation and neovascularization.